NasdaqCM - Nasdaq Real Time Price USD

SAB Biotherapeutics, Inc. (SABS)

Compare

3.8400

-0.2800

(-6.80%)

At close: January 10 at 4:00:00 PM EST

4.0300

+0.19

+(4.95%)

After hours: January 10 at 6:24:29 PM EST

SAB Biotherapeutics Leads The Pack Of 3 US Penny Stocks To Consider

As the United States stock market navigates a complex landscape of inflation data and interest rate adjustments, investors are exploring diverse opportunities across various sectors. The term 'penny stocks' may seem outdated, but these smaller or newer companies can still offer potential for growth when they possess strong financial fundamentals. In this article, we explore three U.S. penny stocks that stand out for their financial resilience and potential to deliver value to investors...

Simply Wall St. 20 days ago

SABS
-6.80%
SABSW

DDL
These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts

The year is winding down, but the bull markets are still charging ahead, getting a boost from improved sentiment after the presidential election. While the next few months will be a time of transition, a few things are likely. The Trump administration is expected to pursue a far looser regulatory policy than the outgoing Biden government. Plans for individual tax cuts are projected to drive consumer spending, while reductions in corporate taxes could deliver an immediate boost to earnings. While

TipRanks last month

GNLX

SABS
-6.80%
SABSW
SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)

SAB Biotherapeutics ( NASDAQ:SABS ) Third Quarter 2024 Results Key Financial Results Net loss: US$10.3m (loss widened...

Simply Wall St. 2 months ago

SABS
-6.80%
SABSW
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year. MIAMI, Nov. 06, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported fin

GlobeNewswire 2 months ago

SABS
-6.80%
SABSW
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference

MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Chairman and CEO Samuel J. Reich will be speaking at an upcoming fireside chat at the 2024 Guggenheim Securities Healthcare Innovation Conference held November 11th – 13th, 2024 in Boston, M

GlobeNewswire 2 months ago

SABS
-6.80%
SABSW
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Simply Wall St. 3 months ago

SABS
-6.80%
SABSW
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of T1D, today announced that Chairman and CEO Samuel J. Reich will be participating in a fireside chat at the 2024 Cantor Global Healthcare Conference, September 17-19th, 2024. Fireside Chat: September 18th, 2024, at 8:00 am ETLocation:

GlobeNewswire 3 months ago

SABS
-6.80%
SABSW
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting

SAB-142 has completed Phase 1 enrollment of all planned cohorts in healthy volunteers and is progressing to enroll patients with type 1 diabetes in the last cohort of the study. Target dose of SAB-142 2.5mg/kg completed with no observation of serum sickness. SAB-142 remains on track for a topline Phase 1 data readout by the end of the year. MIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunother

GlobeNewswire 4 months ago

SABS
-6.80%
SABSW
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it will present at the European Association for the Study of Diabetes 60th Annual Meeting on September 9, 2024 in Madrid. SAB’s Executive Vice President and Chief Medical Officer Alexandra

GlobeNewswire 4 months ago

SABS
-6.80%
SABSW
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

FDA provided clearance to SAB’s IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30,

GlobeNewswire 5 months ago

SABS
-6.80%
SABSW
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced the founding of a clinical advisory board to provide expert insight and guidance to the Company in the clinical development of SAB-142, its leading therapeutic candidate. The ne

GlobeNewswire 5 months ago

SABS
-6.80%
SABSW
SAB BIO Appoints Lucy To as Chief Financial Officer

MIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Lucy To has been named Chief Financial Officer effective August 12, 2024. Ms. To brings over 18 years of investment banking and strategic operational expertise to SA

GlobeNewswire 5 months ago

SABS
-6.80%
SABSW
SAb Biotherapeutics Rebrands as SAB BIO

New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced its new name, SAB BIO

GlobeNewswire 6 months ago

SABS
-6.80%
SABSW
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it will present a poster at the ADA 84th Scientific Sessions on June 21-24, 2024 in Orlando, Florida. The poster will be presented by SAB’s Senior Program Manager, Eric Sandhurst

GlobeNewswire 6 months ago

SABS
-6.80%
SABSW
SAB Biotherapeutics Announces Departure of Chief Financial Officer

MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of T1D, today announced that effective June 4, its Chief Financial Officer Michael King will be departing the company to accept a role as CEO at a privately-held oncology company. He will continue as an advisor to SAB through

GlobeNewswire 7 months ago

SABS
-6.80%
SABSW
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

This regulatory clearance enables clinical development of SAB-142 in patients with type 1 diabetes in the USMIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), today announced that the U.S. Food and Drug Administration (FDA) has provided clearance for the Company’s investigational new drug (IND) application to proceed for its phase 1 clinical trial for type 1 diabetes (T1D) therapy SAB-142. SAB is a clinical-stage biopharmaceutical company with a

GlobeNewswire 7 months ago

SABS
-6.80%
SABSW
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

MIAMI, May 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the first quarter ended March 31, 2024, and provided a company update.“As we work towards upcoming SAB-142 milestones, I remain enthusiastic about our

GlobeNewswire 7 months ago

SABS
-6.80%
SABSW
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Jay Skyler, MD, MACP, FRCP has been appointed to the company’s Board of Directors. “Dr. Skyler’s appointment to our Board of Directors is a major milestone for SAB,” said Samuel J

GlobeNewswire 8 months ago

SABS
-6.80%
SABSW
SAB Biotherapeutics Provides SAB-142 Trial Update

MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA disclosed that SAB has completed dosing the third cohort for SAB-142 with no observation of ser

GlobeNewswire 8 months ago

SABS
-6.80%
SABSW
SAB Biotherapeutics to Present at INNODIA Annual Meeting

MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA will share an overview of the SAB-142 clinical development plan and anticipated milestones at t

GlobeNewswire 9 months ago

SABS
-6.80%
SABSW

Performance Overview

Return	SABS	S&P 500
YTD	-7.47%	-1.35%
1-Year	-35.35%	+22.51%
3-Year	-94.79%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics Leads The Pack Of 3 US Penny Stocks To Consider

These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts

SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference

SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

SAB BIO Appoints Lucy To as Chief Financial Officer

SAb Biotherapeutics Rebrands as SAB BIO

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

SAB Biotherapeutics Announces Departure of Chief Financial Officer

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

SAB Biotherapeutics Provides SAB-142 Trial Update

SAB Biotherapeutics to Present at INNODIA Annual Meeting

Performance Overview